TaiGen Biopharmaceuticals Holdings Ltd (太景醫藥研發控股) last quarter swung into a net loss of NT$102 million (US$3.34 million) due to falling revenue, and high research and development expenses.
That compared with a net profit of NT$60.45 million in the second quarter on the back of a one-time milestone payment of US$5 million for its hepatitis C drug Furaprevir.
However, last quarter’s losses contracted 17 percent from a year earlier thanks to a 36 percent decline in non-operating costs to NT$36.76 million, the Taipei-based company said.
Revenue fell 3 percent from a year earlier to NT$4.79 million during the July-to-September period, as sales of its oral formulation of antibiotic Taigexyn, used for pneumonia treatment, slowed down due to fewer patients in the hot season, TaiGen told an investors’ conference in Taipei on Tuesday.
Net losses totaled NT$96.37 million in the first three quarters of this year, down 61 percent from net losses of NT$247 million a year earlier, company data showed.
Losses per share were NT$0.13, compared with NT$0.35 a year earlier.
TaiGen said sales of Taigexyn would rebound this quarter, as pneumonia cases are expected to increase over the winter.
Revenue last month rose 2.4 times annually to NT$5.5 million, thanks to massive purchases of the drug by its local marketing partner, Holding Disp Co Ltd (文德藥業), TaiGen said.
“Overall, the sale of Taigexyn posted rapid growth in China and in Taiwan this year, but there is still a cap on the drug’s sales, as it has not been included in the public health insurance program in China,” Taigen chairman Philip Huang (黃國龍) said.
The company has negotiated with Chinese regulators to have Taigexyn included in the insurance program and is awaiting their decision, Huang said.
The drug last year was added to the National Health Insurance program.
As for the intravenous formulation of Taigexyn, which TaiGen has said would be more popular and profitable than the oral formulation, the firm reiterated that it could start selling the drug in China next year, as it expects to gain marketing approval soon.
Meanwhile, TaiGen has submitted a pre-investigational new drug application to the Chinese National Medical Products Administration for its new anti-influenza drug TG-1000, Huang said.
The new drug would be a more effective treatment than the anti-flu drug oseltamivir, which is sold under the brand name Tamiflu, as people can take TG-1000 within 72 hours of the onset of symptoms, while Tamiflu has to be taken within 48 hours, Huang said.
If the new drug’s application and clinical trials proceed smoothly, it could obtain marketing approval in three to four years, he added.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
TRANSFORMATION: Taiwan is now home to the largest Google hardware research and development center outside of the US, thanks to the nation’s economic policies President Tsai Ing-wen (蔡英文) yesterday attended an event marking the opening of Google’s second hardware research and development (R&D) office in Taiwan, which was held at New Taipei City’s Banciao District (板橋). This signals Taiwan’s transformation into the world’s largest Google hardware research and development center outside of the US, validating the nation’s economic policy in the past eight years, she said. The “five plus two” innovative industries policy, “six core strategic industries” initiative and infrastructure projects have grown the national industry and established resilient supply chains that withstood the COVID-19 pandemic, Tsai said. Taiwan has improved investment conditions of the domestic economy
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day